P754: INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH FLT3 OR CBL MUTATION

Slični predmeti

• Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
  od: Sangeetha Venugopal, i dr.
  Izdano: (2022-01-01)
• Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
  od: Patrick K. Reville, i dr.
  Izdano: (2021-03-01)
• Acute myeloid leukemia: current progress and future directions
  od: Hagop Kantarjian, i dr.
  Izdano: (2021-02-01)
• Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
  od: Prajwal Boddu, i dr.
  Izdano: (2017-08-01)
• Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
  od: Prajwal Boddu, i dr.
  Izdano: (2018-09-01)